WO2022059498A1 - 三次元筋組織構築デバイス及び三次元筋組織の製造方法 - Google Patents
三次元筋組織構築デバイス及び三次元筋組織の製造方法 Download PDFInfo
- Publication number
- WO2022059498A1 WO2022059498A1 PCT/JP2021/032244 JP2021032244W WO2022059498A1 WO 2022059498 A1 WO2022059498 A1 WO 2022059498A1 JP 2021032244 W JP2021032244 W JP 2021032244W WO 2022059498 A1 WO2022059498 A1 WO 2022059498A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- muscle tissue
- culture
- support member
- culture solution
- connector
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 137
- 238000000034 method Methods 0.000 title description 28
- 210000004683 skeletal myoblast Anatomy 0.000 claims abstract description 37
- 239000000017 hydrogel Substances 0.000 claims abstract description 30
- 238000012258 culturing Methods 0.000 claims abstract description 26
- 210000001087 myotubule Anatomy 0.000 claims abstract description 11
- 238000010276 construction Methods 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 9
- 150000003278 haem Chemical class 0.000 claims description 8
- 238000007599 discharging Methods 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 3
- 230000001172 regenerating effect Effects 0.000 abstract description 3
- 230000000451 tissue damage Effects 0.000 abstract 1
- 231100000827 tissue damage Toxicity 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 82
- 210000004027 cell Anatomy 0.000 description 69
- 230000010412 perfusion Effects 0.000 description 48
- 210000001519 tissue Anatomy 0.000 description 33
- 239000000499 gel Substances 0.000 description 16
- 235000015097 nutrients Nutrition 0.000 description 16
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 14
- 239000000512 collagen gel Substances 0.000 description 12
- 239000000306 component Substances 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 11
- 230000008602 contraction Effects 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000001301 oxygen Substances 0.000 description 11
- 239000002953 phosphate buffered saline Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 10
- 238000001467 acupuncture Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000003566 sealing material Substances 0.000 description 9
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 108010082117 matrigel Proteins 0.000 description 8
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 7
- 229940072056 alginate Drugs 0.000 description 7
- 235000010443 alginic acid Nutrition 0.000 description 7
- 229920000615 alginic acid Polymers 0.000 description 7
- 229910002092 carbon dioxide Inorganic materials 0.000 description 7
- 239000001569 carbon dioxide Substances 0.000 description 7
- 238000012744 immunostaining Methods 0.000 description 7
- 210000003098 myoblast Anatomy 0.000 description 7
- 210000002235 sarcomere Anatomy 0.000 description 7
- 239000002699 waste material Substances 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108010035532 Collagen Proteins 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 6
- 229920001436 collagen Polymers 0.000 description 6
- 210000003632 microfilament Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 230000005484 gravity Effects 0.000 description 5
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 239000008393 encapsulating agent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000002363 skeletal muscle cell Anatomy 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- 241000270322 Lepidosauria Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000003505 Myosin Human genes 0.000 description 3
- 108060008487 Myosin Proteins 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000006059 cover glass Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000004043 dyeing Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000003365 myofibril Anatomy 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000272517 Anseriformes Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 108091033409 CRISPR Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 108010085895 Laminin Proteins 0.000 description 2
- 102000007547 Laminin Human genes 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000000560 biocompatible material Substances 0.000 description 2
- 229920005839 ecoflex® Polymers 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 235000019688 fish Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- -1 for example Substances 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000010872 live dead assay kit Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000010825 Actinin Human genes 0.000 description 1
- 108010063503 Actinin Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000269350 Anura Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108091016585 CD44 antigen Proteins 0.000 description 1
- 238000010354 CRISPR gene editing Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000269333 Caudata Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 241000270722 Crocodylidae Species 0.000 description 1
- 241000252233 Cyprinus carpio Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000009331 Experimental Sarcoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102000008055 Heparan Sulfate Proteoglycans Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000269622 Salamandridae Species 0.000 description 1
- 101100173586 Schizosaccharomyces pombe (strain 972 / ATCC 24843) fft2 gene Proteins 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- 241000271567 Struthioniformes Species 0.000 description 1
- 108090000054 Syndecan-2 Proteins 0.000 description 1
- 241000270666 Testudines Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000007688 edging Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- 239000005431 greenhouse gas Substances 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000007758 minimum essential medium Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000001988 somatic stem cell Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002948 striated muscle cell Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M21/00—Bioreactors or fermenters specially adapted for specific uses
- C12M21/08—Bioreactors or fermenters specially adapted for specific uses for producing artificial tissue or for ex-vivo cultivation of tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M23/00—Constructional details, e.g. recesses, hinges
- C12M23/40—Manifolds; Distribution pieces
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M29/00—Means for introduction, extraction or recirculation of materials, e.g. pumps
- C12M29/10—Perfusion
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- the present invention mainly relates to a three-dimensional muscle tissue construction device and a method for manufacturing a three-dimensional muscle tissue.
- Meat demand is increasing with the increase in population and income in emerging countries.
- it is difficult to increase the supply of meat due to the soaring price of grains used as feed for livestock and the problem of securing a breeding place, and the development of alternative meat is expected.
- Cultured meat is made by forming tissue using skeletal muscle cells increased by culture. Since it can be produced in the laboratory, it can be produced without being affected by climate change, and has less greenhouse gas emissions and less environmental load than conventional livestock.
- An object of the present invention is to provide a three-dimensional muscle tissue constructing device for manufacturing a three-dimensional muscle tissue and a method for manufacturing a three-dimensional muscle tissue.
- the present invention provides the following three-dimensional muscle tissue constructing device and a method for manufacturing a three-dimensional muscle tissue.
- a first muscle tissue anchor engaged with a first support member and / or a first connector A three-dimensional muscle tissue building device with a second muscle tissue anchor engaged to a second support member and / or a second connector.
- the three-dimensional muscle tissue construction device according to [1], further comprising a first support member and a flow path forming member for a culture solution that engages with the second support member.
- the three-dimensional muscle tissue construction device according to [1] or [2], further comprising a pump for supplying the culture solution to the culture solution inlet.
- a hydrogel containing skeletal myoblasts is obtained with the flow path forming member inserted through the first support member and the second support member.
- a method for producing three-dimensional muscle tissue which comprises a step of supplying to and culturing skeletal myoblasts in three dimensions.
- the present invention specifically provides a three-dimensional muscle tissue construction device and a manufacturing method.
- a three-dimensional muscle tissue having a sufficient thickness can be produced. Therefore, the three-dimensional muscle tissue produced by the present invention can be expected to have a texture similar to that of edible steak meat. Further, in regenerative medicine applications, by using thick three-dimensional muscle tissue, it can be expected that damage to a wide range of thick muscle tissue can be repaired with a single treatment.
- the schematic diagram which shows the outline of the 3D muscle tissue construction device of this invention.
- An embodiment of the three-dimensional muscle tissue construction device of the present invention is shown.
- Procedure for forming a three-dimensional muscle tissue-building device during parallel culture Procedure for forming a three-dimensional muscle tissue-building device during vertical culture.
- V and H represent the vertical direction and the horizontal direction, respectively.
- HE-stained image Comparison of (a) perfused tissue, (b) non-perfused tissue, and (c) cell concentration.
- Comparison of (a) perfused tissue, (b) non-perfused tissue, and (c) cell concentration Photographs of the tissue surface and interior. Orientation index inside the tissue.
- the three-dimensional muscle tissue construction device 1 of the present invention includes a first connector 4 and a second connector 5 facing each other, and a flow path 3 of a culture solution is formed between the first support member 8 and the second support member 9. There is.
- the flow path 3 has a solid flow path forming member 10 (FIG. 5B) such as a wire, a wire, and an acupuncture beam between the first support member 8 and the second support member 9. It can be formed by filling the culture space 2 between the first connector and the second connector with a hydrogel containing skeletal myoblasts in the inserted state, and pulling out the flow path forming member 10 after the hydrogel has hardened. ..
- the flow path 3 in this case is a cavity between the first connector 4 and the second connector 5 formed in the three-dimensional muscle tissue 16.
- the channel forming member 10 Since the channel forming member 10 is withdrawn after injecting a hydrogel containing skeletal myoblasts into the culture space, it is preferable to coat the surface thereof with a material that suppresses cell adhesion, for example, bovine serum albumin (BSE).
- BSE bovine serum albumin
- Hydrogels containing skeletal myoblasts have fluidity that allows injection when injected into the culture space, but after a while the gel hardens to gain sufficient strength and shape retention.
- the hole through which the flow path forming member 10 of the first connector 4 passes is closed with the sealing material 20.
- the second connector 5 has a hole for passing the flow path forming member 10
- the hole for passing the flow path forming member 10 of the second connector 5 may be similarly closed with the sealing material 20.
- the first connector 4 and the sealing material 20 may be integrally molded. Even if the first connector 4 and the sealing material 20 are integrated, there is no particular problem as long as the culture solution can be circulated.
- the flow path 3 has a gas component such as oxygen or carbon dioxide and / or a nutrient 14 (hereinafter, “nutrient, etc.” between the first support member 8 and the second support member 9).
- a hollow flow path forming member 10 through which waste products can pass is attached, and the culture solution 15 is allowed to flow inside the flow path forming member 10, so that nutrients and the like can be contained inside the three-dimensional muscle tissue. 14 can be supplied and carbon dioxide and waste products can be discharged.
- the flow path 3 of the culture solution 15 in this case is a cavity inside the flow path forming member 10.
- the culture solution 15 is supplied to the culture solution introduction port 6 by the pump 12, flows from the first support member 8 into the second support member 9 through the flow path 3, and contains waste products that have passed through the second support member 9.
- the culture solution 15 is discharged from the culture solution discharge port 7 formed in the second connector 5.
- the first support member 8 and the second support member 9 are provided with an opening for inserting the flow path forming member 10.
- the encapsulant 20 is a encapsulant for encapsulating the opening on the first support member side, and the encapsulant 20 allows the culture broth 15 introduced from the culture broth introduction port 6 to pass through the flow path 3. It flows in the direction of the arrow in FIG.
- the sealing material 20 for example, Ecoflex (registered trademark) manufactured by BASF can be used.
- the opening 5a on the second support member side is not sealed in FIGS. 1 and 2, a part of the culture solution that has passed through the second support member 9 is directly discharged from the culture solution discharge port 7. A part of the mixture is mixed with the culture solution 15 outside the culture space and discharged from the culture solution discharge port 7.
- the opening on the side of the second support member 8 may be sealed with the sealing material 20.
- the culture solution may be discharged from the culture solution discharge port 7, but by arranging the tip of the discharge tube in the culture solution outside the muscle tissue 16, the culture solution outside the muscle tissue and the flow path 3
- the culture broth containing the waste products that have passed through the above may be mixed, and the mixed culture broth may be discharged.
- the surface of the culture (three-dimensional muscle tissue 16) of the skeletal myoblast 13 is sufficiently supplied with nutrients 14 from the culture solution 15, and the inside of the muscle tissue 16 is nutrients from the fresh culture solution flowing through the flow path 3.
- Etc. 14 are supplied, and the waste liquid having a high concentration of carbon dioxide and waste products is discharged from the culture liquid discharge port 7.
- the culture broth circulates, but the culture broth discharged from the culture broth outlet may be discarded and fresh culture broth may be supplied from the culture broth introduction port 6 by the pump 12.
- a syringe pump can be used as the pump 12.
- the pump 12, the culture solution introduction port 6, and the culture solution discharge port 7 may be connected by a tube.
- the system of the present invention may include electrodes (not shown).
- the construction of muscle tissue can be promoted. If the culture solution 15 is sufficiently abundant in the culture tank, the culture solution 15 may be circulated, but if the culture solution 15 is small, the old culture solution 15 that has passed through the flow path 3 should be discarded. Is desirable.
- first support member and the second support member are arranged on a straight line to form a straight flow path.
- the distance between adjacent flow paths depends on the thickness (diameter or cross-sectional area) of the flow paths, but is preferably about 500 to 1500 ⁇ m.
- the peripheral portion of the muscle tissue 16 is sufficiently supplied with nutrients 14 from the culture solution 15, so that the skeletal myoblast 13 proliferates well. Since the supply of nutrients and the like 14 is insufficient inside the muscle tissue 16, the thicker the muscle tissue 16 is, the more likely the cultured cells are to die. In the present invention, nutrients and the like 14 are evenly supplied to the periphery and the inside of the muscle tissue 16, and carbon dioxide and waste products are discharged. Therefore, a thick muscle tissue 16 can be obtained in a short period of time, and the surface and the inside muscle tissue 16 can be obtained. The difference does not matter.
- the shapes of the first and second muscle tissue anchors 11 are not particularly limited, but mesh-like ones as shown in FIGS. 4A to 4C are preferable.
- the muscle tissue 16 is entwined with the mesh-shaped anchor 11 and both ends are fixed.
- the skeletal myoblast 13 contracts when the culture is continued, but is fixed by the anchors 11 on both sides, so that the thick muscle tissue 16 can be maintained even if the culture is continued. Since the skeletal myoblast 13 contracts as the culture is continued, in FIGS. 1 to 3, the vicinity of the central portion is slightly recessed.
- electrical stimulation may be applied to promote the proliferation of the skeletal myoblast 13.
- FIG. 5 and 6 schematically show the procedure of the method for producing a three-dimensional muscle tissue of the present invention.
- the first connector 4, the second connector 5, and the muscle tissue anchor 11 are fixed to the base material 17.
- the culture space 2 is formed by inserting the flow path forming member 10 through the first support member 8 and the second support member 9 and further fixing the two front and rear side walls 18 to the base material 17.
- FIG. 5C is a diagram when the culture space 2 is filled with a hydrogel containing skeletal myoblast 13.
- FIG. 6A shows a state in which the flow path forming member 10 is pulled out and the two front and rear side walls 18 are further removed.
- FIG. 6B the culture solution is flowed from the culture solution introduction port 6 toward the culture solution discharge port 7, and the culture is started.
- Hydrogel containing skeletal myoblast 13 was injected into the gap of the culture space 2 in which the muscle tissue anchor 11, the first support member 8, the second support member 9, the flow path forming member 10, and the like were housed. After standing for a while, the gel solidifies and retains its shape, after which the side wall 18 is removed.
- the time required for the gel to harden varies depending on the type of hydrogel and the environment, and therefore needs to be adjusted as appropriate. For example, about 30 minutes for collagen gel and about 12 hours for matrigel.
- FIG. 6 is a diagram when the culture solution is flowed in the horizontal direction
- FIG. 7 is a diagram when the culture solution is flowed in the vertical direction.
- the embodiment shown in FIG. 7 is preferable because there is no possibility that the flow path is narrowed by the action of gravity of the muscle tissue.
- the oxygen concentration in the culture solution is preferably 80% or more of the saturated oxygen concentration.
- the muscle tissue anchor can be coated with a biocompatible material to enhance the adhesion of skeletal myoblasts and prevent the muscle tissue from falling off during culture.
- biocompatible materials include fibronectin.
- myotubes are formed when the culture of skeletal myoblasts is continued.
- Hydrogels used for culturing skeletal myoblasts include fibrin, fibronectin, laminin, collagen (eg, type I, type II, type III, type V, type XI, etc.), agar, agarose, glycosaminoglycan, etc. Hydrogels of components constituting the extracellular basement membrane matrix such as hyaluronic acid and proteoglycan can be used. Commercially available products can also be used as hydrogels, for example, components based on mouse EHS tumor extracts (including type IV collagen, laminin, heparan sulfate proteoglycan, etc.) sold under the trade name "Matrigel". Can be done.
- collagen includes undenatured collagen and denatured collagen.
- Gelatin is exemplified as the denatured collagen.
- the hydrogel preferably contains collagen, preferably undenatured type I collagen, especially when the skeletal myoblasts are derived from bovine.
- type I collagen is contained, the content thereof is preferably 0.3 mg / mL or more, more preferably 1.0 to 3.0 mg / mL, and further preferably 1.0 to 1.5 mg / mL.
- the skeletal myoblasts in the hydrogel have, for example, a cell concentration of about 1.0 ⁇ 10 6 cells / ml or more, preferably about 1.0 ⁇ 10 7 cells / mL to about 1.0 ⁇ 10 8 cells / mL, more preferably 5.0 ⁇ 10 7 It is preferably cells / mL to about 1.0 ⁇ 10 8 cells / mL.
- Skeletal myoblasts contained in hydrogel can be prepared by a known method.
- primary myoblasts obtained by treating a muscle tissue derived from a living body with a degrading enzyme for example, collagenase
- Primary myoblasts are preferably filtered to remove impurities such as connective tissue.
- skeletal myoblast cells derived from somatic stem cells capable of differentiating into pluripotent stem cells such as ES cells and iPS cells and skeletal myoblasts can also be used.
- Skeletal myoblasts are derived from vertebrates such as mammals, birds, reptiles, amphibians, and fish.
- mammals include non-human mammals such as monkeys, cows, horses, pigs, sheep, goats, dogs, cats, guinea pigs, rats, and mice.
- birds include ostriches, chickens, ducks, sparrows and the like.
- reptiles include snakes, crocodiles, lizards, turtles and the like.
- amphibians include frogs, newts, salamanders and the like.
- fish include salmon, tuna, shark, Thailand, and carp.
- the skeletal myoblasts are preferably derived from mammals bred for livestock such as cattle, pigs, sheep, goats, and horses, and more preferably derived from cattle.
- a skeletal myoblast genetically modified by a genome editing method such as a homologous recombination method or a CRISPR / Cas9 method or a non-genetically modified skeletal myoblast can be used.
- a genome editing method such as a homologous recombination method or a CRISPR / Cas9 method
- a non-genetically modified skeletal myoblast can be used.
- the culture medium can contain medium components (for example, various amino acids, inorganic salts, vitamins, etc.), serum components (for example, growth factors such as IGF-1, bFGF, insulin, testosterone, etc.), antibiotics, and the like.
- medium components for example, various amino acids, inorganic salts, vitamins, etc.
- serum components for example, growth factors such as IGF-1, bFGF, insulin, testosterone, etc.
- antibiotics and the like.
- the three-dimensional muscle tissue mainly means artificially manufactured muscle that is not derived from a living body.
- the three-dimensional muscle tissue of the present invention is composed of skeletal muscle cells (striated muscle cells).
- Skeletal muscle cells are a form of myotubes (myotube cells) or muscle fibers in which myoblasts, which are precursors thereof, are multinucleated.
- myofibrils are composed of myofibrils composed of actin fibers (actin filaments), which are proteins constituting muscles, and myosin fibers (myosin filaments), which are proteins constituting muscles. Furthermore, myofibrils have a structure in which a plurality of sarcomere structures are connected in the long axis direction. It is known that muscle contraction and relaxation occur based on the interaction (slip) of actin and myosin in sarcomere.
- the preferred three-dimensional muscle tissue of the present invention has a sarcomere structure. However, it does not matter whether or not slippage occurs in the sarcomere structure.
- Whether or not the three-dimensional muscle tissue has a sarcomere structure can be evaluated by a known method. For example, the presence of sarcomeric ⁇ -actinin (SAA), which is a protein constituting the Z membrane of sarcomere structure, was evaluated by immunostaining for SAA, and SAA immunostaining was positive and SAA was distributed in regular stripes. If so, it can be determined to have a sarcomere structure.
- SAA sarcomeric ⁇ -actinin
- the muscle fibers are aligned and oriented in the same direction.
- the orientation of muscle fibers can be assessed, for example, by immunostaining with SAA.
- the components (preferably all components) used in the production method of the present invention satisfy predetermined criteria and are used for food production and / or food. It is preferable, but not limited to, the ingredient in which the safety of the above is ensured.
- Skeletal myoblasts can be cultured, for example, in the above-mentioned medium for growth culture by a method known to those skilled in the art.
- a suitable culturing method a method of culturing under conditions of about 37 ° C. and a carbon dioxide concentration of about 5 to 10% (v / v) is exemplified, but the method is not limited thereto. Culturing under the above conditions can be performed using, for example, a known CO 2 incubator.
- serum components for example, horse serum (Horse)
- a normal liquid medium such as DMEM (Dulbecco's Modified Eagle's Medium), EMEM (Eagle's minimal essential medium), ⁇ MEM (alpha Modified Minimum Essential Medium).
- Serum Fetal bovine serum (FBS), human serum (Human Serum), etc.), components such as growth factors; culture medium supplemented with antibiotics such as penicillin and streptomycin can be used.
- fetal bovine serum When adding a serum component to a medium for growth culture, fetal bovine serum can be used as the serum component.
- concentration of serum components can be about 10% (v / v).
- the culture period can be, for example, about 1 day to 2 weeks.
- skeletal myoblasts can be induced to differentiate into myotubes.
- This differentiation induction skeletal myoblasts are multinucleated by cell fusion with surrounding cells, and myotubes are formed.
- the myotubes form muscle fibers as they mature further.
- the above culture can be carried out, for example, in a medium for inducing differentiation (culture for multinucleation) by a method known to those skilled in the art.
- a suitable culturing method a method of culturing under conditions of about 37 ° C. and a carbon dioxide concentration of about 5 to 10% (v / v) is exemplified, but the method is not limited thereto. Culturing under the above conditions can be performed using, for example, a known CO 2 incubator.
- myoblasts become low in nutrients, they involve surrounding cells and start polynuclearization. Therefore, it is preferable to induce differentiation into myotubes using a medium having less nutrients than the above-mentioned growth culture. Since horse serum is known to have less nutrients than fetal bovine serum, horse serum can be used. The concentration of serum components can be about 2% (v / v).
- the flow path through which the culture solution flows may be in the horizontal direction or in the vertical direction. It is preferable that the flow path is in the vertical direction because the flow path can be prevented from being narrowed by its own weight.
- the three-dimensional muscle tissue of the present invention does not have to contain heme. This is because the present invention does not require a heme to supply oxygen to the cells. It should be noted that heme that is slightly mixed during cell collection and heme that is added not for the purpose of supplying oxygen but for coloring and flavoring are treated as additives and are not regarded as heme in the present invention.
- Example 1 Preparation of Support Member with Anchor
- the support member 8 or 9 and the muscle tissue anchor 11 are vertically arranged in a mesh shape of three rows, and the support member with an anchor is arranged.
- the muscle tissue anchor 11 fixes the contracting muscle tissue
- the support members 8 and 9 supply nutrients to the inside of the muscle tissue by the culture solution.
- the first connector 4 and the second connector 5 fix the muscle tissue anchor 11 and the first support member 8 or the second support member 9.
- the hole through which the flow path forming member 10 is passed is closed with a sealing material 20 (Ecoflex (registered trademark) manufactured by BASF), but the second connector 5 is used. Since there is a hole through which the channel forming member 10 passes, the culture solution that has passed through the channel is mixed with the culture solution in the culture space and discharged from the culture solution discharge port.
- a sealing material 20 Ecoflex (registered trademark) manufactured by BASF
- the support member with an anchor shown in FIG. 4 was manufactured using a stereolithography machine (DigitalWax028J, DWS).
- the resin used for DWS was a DWS exclusive resin (DM210).
- the muscle tissue anchor 11, the first support member 8 and the second support member 9 were coated with PMBV631 (2 wt% ethanol) and then coated overnight with fibronectin (10 ⁇ L), which promotes cell adhesion. Acupuncture needles were coated with bovine serum albumin (BSA, 1%) for 1 hour to suppress cell adhesion.
- BSA bovine serum albumin
- C2C12 myoblast was used. 2.0 ⁇ 10 6 cells were seeded on a 150 mm dish, and the cells passaged 2 days later were used as cells, all of which were P11 (11 passages) or less. The cell concentration was 4.0 ⁇ 10 7 cells / mL.
- Injection of hydrogels containing skeletal myoblasts (C2C12) into the device was performed as follows. After adding 3 mL of trypsin to the dish in which C2C12 was growing, the cells were detached from the dish by incubating at 37 ° C for 5 minutes. After adding 7 mL of Dulbecco's modified Eagle's medium (DMEM) to the dish, pipette twice with an electric pipette to collect 50 mL. The cells were precipitated by centrifugation at 200 g for 3 minutes. Subsequent work was done on ice.
- DMEM Dulbecco's modified Eagle's medium
- parallel culture means culturing with the flow path 3 perpendicular to the direction of gravity.
- the two anchored support members are arranged facing each other, and the first connector 4 and the second connector 5 are fixed to the base material 17.
- An acupuncture needle (SJ-217, manufactured by Seirin Corporation) is inserted into the first support member and the second support member, and the side wall 18 is attached to the base material 17 to form the culture space 2.
- 3. 3. Inject hydrogel containing C2C12 into the culture space and incubate for 30 minutes at 37 ° C to solidify the hydrogel.
- 4. 3. 3. Place the device obtained in step 1 in a 25 mL tube, soak it in the culture medium, and let it stand for 30 minutes. 5.
- the acupuncture needle is pulled out to form a channel 3. 6. 5. Transfer the device obtained in step 1 to a dish and remove the side wall 18. 7. The sealing material 20 closes the hole for inserting the needle on the culture solution introduction port 6 side. 8.
- One perfusion tube is connected to the culture solution inlet 6, and the other perfusion tube is placed near the liquid surface to perfuse the culture solution.
- the two perfusion tubes are connected to a syringe pump, and the culture solution is perfused by the syringe pump. In the above "8.”, the other perfusion tube is inserted below the culture solution surface, but it may be connected to the culture solution discharge port 7.
- vertical culture means culturing with the flow path 3 parallel to the direction of gravity.
- the two anchored support members are arranged facing each other, and the first connector 4 and the second connector 5 are fixed to the base material 17.
- An acupuncture needle (SJ-217, manufactured by Seirin Corporation) is inserted into the first support member and the second support member, and the side wall 18 is attached to the base material 17 to form the culture space 2.
- 3. 3. Inject hydrogel containing C2C12 into the culture space and incubate for 30 minutes at 37 ° C to solidify the hydrogel. 4.
- the perfusion tube is connected to the culture solution inlet 6. 5. 4. Place the device obtained in step 1 in a 100 mL tube and bring the electrodes closer together.
- the tube was shaken with a shaker and rotated at 60 rpm for culture.
- the oxygen concentration that can be taken in only from the surface of the culture solution can be made constant in the culture solution.
- two syringe pumps to which the tubes are connected are prepared, the tube for injecting the medium is placed above the liquid surface, and the tube for sucking the medium is brought close to the bottom, for suction and injection.
- tissue sections of three-dimensional muscle tissue were prepared. Section preparation was performed in the order of (i) cryoprotect treatment, (ii) freezing treatment, (iii) section preparation, (iv) HE staining, and (v) immunostaining.
- Cryoprotect treatment is a treatment to prevent the formation of ice particles in the tissue when frozen.
- PBS refers to phosphate buffered saline.
- Freezing treatment Frozen treatment is performed before preparation of frozen sections. 1. Pour liquid nitrogen into a heat insulating container (height 4-5 cm). 2. Place the cryodish in liquid nitrogen using tweezers. 3. If you soak in liquid nitrogen for a long time, the 3D muscle tissue will crack, so take the cryodish in and out every 1-2 seconds to gradually harden the 3D muscle tissue.
- Section preparation Using a cryostat section is prepared to a thickness of 8 ⁇ m.
- 1. Place the cryodish containing the frozen 3D muscle tissue sample in the cryostat and warm to -20 ° C. 2. Remove the sample from the cryodish and make a short side with a thickness of 8 ⁇ m. 3. Rotate the sample 180 degrees to make a short side with a thickness of 8 ⁇ m on the opposite side. 4. Rotate the sample 90 degrees to make 3 to 4 long sides with a thickness of 8 ⁇ m. 5. Cut the sample by 200 ⁇ m and repeat the preparation of the long side until the long side disappears. 6. Attach the obtained section to MAS coated glass.
- HE staining The procedure for HF staining is as follows. 1. Dry for 1 day after making the section. 2. Soak the section in Meyer's hematoxylin solution and let stand for 5 minutes. 3. Adsorb and remove excess hematoxylin solution on paper. 4. Transfer the sections to a stain bottle containing water and remove excess stain. 5. Soak in warm water at 50 ° C and let stand for 5 minutes. 6. Transfer the sections to a stain bottle containing water. 7. Soak in eosin solution and let stand for 5 minutes. 8. Soak in 100% ethanol and slowly move the glass slide up and down 5 times to remove excess stain. 9. Repeat step 8 above, changing the bottle, a total of 3 times. 10. Soak in xylene (3 times for 5 minutes each). 11. Enclose a few drops of canard new in a section and attach a cover glass. 12. Allow to dry overnight.
- the three-dimensional muscle tissue prepared by the present invention is characterized by being oriented.
- the orientation index evaluation of the three-dimensional muscle tissue was performed by the following procedure using the two-dimensional Fourier transform. 1. Cut so that the vertical and horizontal dimensions are power pixels of 2. 2. Make it gray. 3. Put on the honey window. 4. Two-dimensional Fourier transform is performed using the function fft2 of numerical analysis software (MATLAB (registered trademark), provided by MathWorks). 5. Integrate the 2D Fourier transform image for polar constellation and add the pixel values from 1 degree to 180 degrees. 6. From 1 degree to 180 degrees, divide by the sum of the totals to get the average.
- MATLAB registered trademark
- nuclei were discriminated from the HE-stained image using image processing software (ImageJ, open source), and the number of nuclei was counted according to the following procedure. 1. Combine the images using Make composite. 2. Convert to 32-bit RGB color using RGB Color. 3. Use Deconvolution to split the RGB color image for HE. 4. Use Threshold for the Blue image to separate the image containing the nucleus from the background. 5. Separate the connected nuclei using Watershed. 6. Count the number of nuclei.
- FIG. 10 shows the results of flowing ink through the flow path 3 in vertical culture and parallel culture.
- FIG. 13 is a photograph in which the tissue after 36 hours is embedded in an alginate gel and an enlarged photograph of a portion of the mesh anchor 11. It was shown that the muscle tissue was anchored even when tension was applied so that the width contracted by 39%.
- FIG. 14 (a) a fluorescence-stained image of the part of the muscle tissue in contact with the medium.
- Red is the actin filament dyed with phalloidin
- blue is the nucleus dyed with Hoechst. It can be confirmed that many nuclei are on one myotube, and it can be seen that myoblasts are fused.
- FIG. 14 (b) is a diagram showing the directional distribution of actin from the image of only the actin filament. Since it can be confirmed that the peak stands at 0 degrees, it can be seen that the muscle tissue is oriented in the direction of O degrees.
- FIG. 15 shows the results of cutting the muscle tissue after culturing and observing the live / dead assay with a confocal microscope. Since it is possible that cells die on the cut surface, the inside of the tissue was observed from the 34 ⁇ m cut surface. There were 196 live cells and 725 dead cells, and the survival rate was as low as 21%. The cause of the low cell viability may be damage during tissue cutting. We are observing the tissue inside 34 ⁇ m from the cut surface of the tissue, but it is possible that the tissue is pulled during cutting and damages the cells.
- Another characteristic result is that there are many live cells between the channels, but there are many dead cells around the channels.
- the oxygen deficiency in culture which is considered to be the cause of cell death
- cells near the channel should be alive, and the number of dead cells should increase as the cells move away from the channel, but the opposite tendency was shown. Therefore, it is considered that the cells did not die during the culture period, but the cells around the channel were damaged and died when the acupuncture needle was pulled out to form the channel. Since the needle is BSA coated, the cells should not be adhered, but it is possible that the cells died due to rubbing when the needle was pulled out. To avoid this, it is necessary to slowly pull out the needle.
- FIG. 16 is a graph of the change in width during culture without shaking. Those that were perfused with an anchor, those that were not perfused with an anchor, and those that were not perfused without an anchor were with perfusion (hereinafter, w / perfusion), without perfusion (hereinafter, w / o perfusion), and without anchor, respectively. (Hereafter, w / o anchor).
- the width was observed by looking at the side of the tube, that is, the curved surface with a camera (VW-600C, KEYENCE). The length was calculated based on the referenceable length of the anchored support member array. The experimental results are the following two.
- the anchor 11 prevents the muscle tissue from falling off in the device of the present invention for culturing the contractile muscle tissue.
- FIG. 18 shows a plot with time taken on the horizontal axis. There are four channels in the tissue, but since they appear to overlap, only two should actually be visible.
- FIG. 21 (a) is an HE-stained image. Since it was a sample that confirmed that perfusion had failed in the ink flow experiment, it was confirmed that there was no nucleus in the center. It is considered that the non-existence is either that the nucleus is enucleated and no longer exists, or that the culture solution is sought and moved to the peripheral part. In particular, as shown in FIG.
- the initial cell concentration of the sample used in this experiment was 4.0 ⁇ 10 7 cells / mL, and considering that the cross section of 16 mm 2 shrank to about 1.3 mm 2 , the cell concentration was 49 ⁇ 10 7 cells / mL. Is.
- FIG. 23 (a) is a sample with perfusion
- FIG. 23 (b) is a sample without perfusion.
- FIG. 23 (a) it can be seen that there is a hole.
- the cell concentrations in the rectangular portion of 100 ⁇ m ⁇ 50 ⁇ m were compared for both samples (Fig. 23 (c)).
- Fig. 23 (c) it was found that the cell concentration decreased in both samples as they moved away from the edge of the tissue, but the decrease in cell concentration slowed in the sample with perfusion. This is thought to be due to the fact that oxygen and nutrients were also supplied from the inside by perfusion.
- FIG. 25 shows the actin filaments and nuclei on the surface of the tissue, and the lower part shows the inside of the tissue similarly dyed.
- the results of the sample, w / o anchor sample are shown.
- FIG. 26 shows the orientation index of the lower actin filament. It was found that the sample with anchor and perfusion (with perfusion) had muscle tissue with a high orientation index.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Sustainable Development (AREA)
- Molecular Biology (AREA)
- Clinical Laboratory Science (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
〔1〕
培養空間を有する培養槽、
前記培養空間内の互いに対向する位置に設けられた第1コネクタと第2コネクタ、
前記第1コネクタに設けられた培養液導入口、
前記第1コネクタに複数設けられ、かつ、前記培養液導入口から導入された培養液を吐出可能な第1支持部材、
前記第2コネクタに複数設けられ、かつ、培養液が流入可能な第2支持部材、
第1支持部材及び/又は第1コネクタに係合された第1筋組織アンカー、
第2支持部材及び/又は第2コネクタに係合された第2筋組織アンカーを備えた、三次元筋組織構築デバイス。
〔2〕
第1支持部材と第2支持部材に係合する培養液の流路形成部材をさらに備える、〔1〕に記載の三次元筋組織構築デバイス。
〔3〕
前記培養液導入口へ培養液を供給するためのポンプをさらに備えた、〔1〕又は〔2〕に記載の三次元筋組織構築デバイス。
〔4〕
〔1〕~〔3〕のいずれかに記載の三次元筋組織構築デバイスにおいて、流路形成部材を第1支持部材と第2支持部材に挿通した状態で骨格筋芽細胞を含むハイドロゲルを第1コネクタと第2コネクタの間の培養空間に充填し、ハイドロゲルが固まった後に前記流路形成部材を脱着し、培養液を前記培養液導入口から第1支持部材を通って第2支持部材に供給し、骨格筋芽細胞を三次元培養する工程を含む、三次元筋組織の製造方法。
〔5〕
培養液を輸送可能な複数の流路、
同一方向に配向した筋線維を備えた、三次元筋組織(ただし、三次元筋組織はヘムを含まない)。
〔6〕
隣接する流路の間隔が500~1500μmである、〔5〕に記載の三次元筋組織。
〔7〕
流路と筋線維の配向方向が略平行である、〔5〕又は〔6〕に記載の三次元筋組織
〔8〕
実質的にヘムを含まない、〔5〕~〔7〕のいずれか1項に記載の三次元筋組織。
本発明の三次元筋組織構築デバイス1は、対向する第1コネクタ4と第2コネクタ5を備え、培養液の流路3が第1支持部材8と第2支持部材9の間に形成されている。
筋組織16の培養時には電気刺激を加え、骨格筋芽細胞13の増殖を促進してもよい。
(I)アンカー付支持部材の作製
図4(A)~(C)に示されるように、3列のメッシュ状に支持部材8又は9と筋組織アンカー11を垂直に配置し、アンカー付支持部材を作製した。
ここで、筋組織アンカー11は収縮する筋組織を固定し、支持部材8、9は、培養液により栄養を筋組織の内部に供給する。また、第1コネクタ4及び第2コネクタ5は、筋組織アンカー11と、第1支持部材8又は第2支持部材9を固定する。
図5(B)に示すように、流路形成部材10としての鍼灸針を、第1支持部材8と第2支持部材9の間に挿入し、さらに前後に側壁18を設けることで培養空間2を形成し、この状態で骨格筋芽細胞を含むハイドロゲルをデバイスに注入する。
C2C12が増殖しているディッシュにトリプシンを3mL追加後に5分間37℃でインキュベートして細胞をディッシュから剥離した。7mLのダルベッコ改変イーグル培地(以下、DMEM)をディッシュに追加後に電動ピペットで2回ピペッティングして50mLに集めた。200gで3分間遠心分離して細胞を沈殿させた。これ以降の作業は氷上で行った。
1. 二つのアンカー付支持部材を向かい合わせに配置し、第1コネクタ4、第2コネクタ5を基材17に固定する。
2. 鍼灸針(SJ-217、セイリン社製)を第1支持部材と第2支持部材に挿通し、基材17に側壁18を取り付けて培養空間2を形成する。
3. C2C12を含むハイドロゲルを培養空間に注入して30分間37℃でインキュベートしてハイドロゲルを固める。
4. 3.で得られたデバイスを25mLチューブに入れ、培養液に浸して30分間静置する。
5. 鍼灸針を抜いて流路3(channel)を形成する。
6. 5.で得られたデバイスをディッシュに移して側壁18を取り除く。
7. 封止材20で培養液導入口6側の針挿入用の孔を塞ぐ。
8. 一方の灌流用のチューブを培養液導入口6につなぎ、他方の灌流用チューブを液面近くに置いて培養液を灌流させる。なお、2本の灌流用チューブはシリンジポンプに接続され、シリンジポンプにより培養液が灌流される。
上記「8.」で、他方の灌流用チューブは培養液面より下に挿入しているが、培養液排出口7につないでもよい。
1. 二つのアンカー付支持部材を向かい合わせに配置し、第1コネクタ4、第2コネクタ5を基材17に固定する。
2. 鍼灸針(SJ-217、セイリン社製)を第1支持部材と第2支持部材に挿通し、基材17に側壁18を取り付けて培養空間2を形成する。
3. C2C12を含むハイドロゲルを培養空間に注入して30分間37℃でインキュベートしてハイドロゲルを固める。
4. 灌流用チューブを培養液導入口6に接続する。
5. 4.で得られたデバイスを100mLチューブに入れて、電極を近づける。
6. 培養液で100mLチューブを満たし、30分間静置する。
7. 鍼灸針を抜いて流路3(channel)を形成する。
6. 側壁18を取り除く。
7. 封止材20で培養液導入口6側の針挿入用の孔を塞ぐ。
8. もう一方の灌流用チューブを液面近くに置いて培養液を吸い上げて灌流させる。なお、2本の灌流用チューブはシリンジポンプに接続され、シリンジポンプにより培養液が灌流される。
切片作製は、(i)クライオプロテクト処理、(ii)凍結処理、(iii)切片作製、(iv)HE染色、(v)免疫染色の順で行った。
クライオプロテクト処理は、凍結させたときに組織内の氷の粒ができにくくするための処理である。なお、以下の記載においてPBSとはリン酸緩衝生理食塩水を指す。
1. PBS(-)で培養物(三次元筋組織)を1回洗った後、10%スクロース/PBS(-)溶液、20%スクロース/PBS(-)溶液、30%スクロース/PBS(-)溶液を含むクライオディッシュに各1日間培養物を浸けた。
2. 洗浄処理及び10%、20%、30%スクロース/PBS(-)溶液への浸漬処理には、アンカー部から切り離した三次元筋組織を用いた。
3. OTCコンパウンド剤で満たしたクライオディッシュ内に筋組織を浸漬し、室温で2日間静置した。
凍結切片の作製の前に凍結処理を行う。
1. 断熱容器に液体窒素を注ぐ(高さ4-5cm)。
2. ピンセットを用いてクライオディッシュを液体窒素の中に入れる。
3. 液体窒素に長時間浸すと三次元筋組織にひびが入るため、1-2秒ごとにクライオディッシュを出し入れして徐々に三次元筋組織を固める。
クライオスタットを使用して、8μmの厚さで切片を作製する。具体的には、
1. 凍結処理した三次元筋組織サンプルを含むクライオディッシュをクライオスタット内に入れて、-20℃まで温める。
2. クライオディッシュからサンプルを取り出し、8μm厚の短辺を作製する。
3. サンプルを180度回転させて反対側の8μm厚の短辺を作製する。
4. サンプルを90度回転させて8μm厚の長辺を3枚から4枚作製する。
5. サンプルを200μm削り、長辺が無くなるまで長辺の作製を繰り返す。
6. 得られた切片をMASコートグラスに貼り付ける。
HF染色の手順は以下の通りである。
1. 切片作成後1日乾かす。
2. 切片をマイヤーヘマトキシリン溶液に浸けて5分間静置する。
3. 余分なヘマトキシリン液を紙に吸着させて除去する。
4. 水を入れた染色瓶に切片を移して、余分な染色液を落とす。
5. 50℃の温水に浸けて5分静置する。
6. 水を入れた染色瓶に切片を移す。
7. エオシン溶液に浸けて5分静置する。
8. 100%エタノールに浸けてスライドグラスをゆっくり5回上下させて余分な染色液を落とす。
9. 上記8.の操作を、瓶を変えて合計3回行う。
10. キシレンに浸ける(5分ずつ3回)。
11. エンテランニューを切片に数滴落として封入し、カバーガラスを付ける。
12. 一晩乾燥させる。
免疫染色の手順は以下の通りである。
1. 切片の周りをパップペンで縁取る。
2. FBS溶液(1% PBS)をパップペンで縁取った内側に滴下して1時間静置してブロッキング。
3. 切片が剥がれないように染瓶に入れてPBSで洗浄する。
4. 一次染色液をパップペンで縁取った内側に滴下して1時間静置する。
5. 切片が剥がれないように染瓶に入れてPBSで洗浄する。
6. 二次染色液をパップペンで、縁取った内側に滴下して1時間静置する。
7. 切片が剥がれないように染瓶に入れてPBSで洗浄する。
8. DAPIを滴下する。
9. カバーガラスをかける。
10. カバーガラス側から観察する。
三次元筋組織の配向指標評価は、2次元フーリエ変換を用いて以下の手順で行った。
1. 縦横が2の累乗ピクセルとなるように切り取る。
2. グレイ化する。
3. ハニング窓をかける。
4. 数値解析ソフトウェア(MATLAB(登録商標)、MathWorks社提供)の関数fft2を用いて二次元フーリエ変換する。
5. 二次元フーリエ変換画像を極座用積分して、1度から180度までのピクセル値を足す。
6. 1度から180度で、それぞれの合計を足した数で割り平均を出す。
1. Make compositeを用いて画像を結合する。
2. RGB Colorを用いて32ビットRGBカラーに変換する。
3. Deconvolution を用いてHE用にRGBカラー画像をスプリットする。
4. ThresholdをBlue画像に用いて核を含む画像を背景と分離する。
5. Watershedを用いて繋がった核を分離する。
6. 核の数を計測する。
(1)デバイスの評価
流路3の形状、及び流れを確認した。
(1-1)流路3の形状
ハイドロゲルとしてコラーゲンゲルを用いて細胞なしのゲル構造体を図4に示す9つの支持部材アレイを用いて製作し、ハイドロゲルを培養空間2に注入して静置し、ゲル化後に流路形成部材としての鍼灸針10を抜き取り、すぐに流路に垂直な断面で切断した。切断する際に流路が潰れることを防ぐために、アルギン酸ゲル溶液を流路に通してゲル化させて流路の形状を保たせた。切断面を確認したところ、孔を9個確認することができた。ゲル化後に針を抜くという流路の作成方法により、流路が形成できることが確認できた。
流路が閉塞していないことを確認するために、流路にインクを流した。
具体的には、コラーゲンゲルを用いて細胞なしのゲル構造体を支持部材において製作し、ゲル化後すぐに青いインクを流した。流している様子を顕微鏡(STZ-171、島津製作所)で動画撮影した。
図9に示すように、流路の中をインクが流れていることが確認できた。
このことから、三次元筋組織の内部に、酸素と栄養分を含む培養液を送液可能であることが明らかになった。
先ず、垂直培養と平行培養の違いを説明する。平行培養の場合において、コラーゲンゲル100%を用いた場合には、7日間培養後にアルギン酸ゲルを培養液導入口6から流し込んだ時に、アルギン酸ゲルが培養液排出口7から排出された。一方、コラーゲンゲルとマトリゲルを併用したゲル(コラーゲンゲル:マトリゲル=50%:50%)を用いた場合は、7日間培養後にアルギン酸ゲルを培養液導入口6から流し込んだ時に、アルギン酸ゲルが培養液排出口7から排出されなかった。これはマトリゲルがコラーゲンゲルより柔らかく、重力によって構造体が変形しやすいため7日間の培養期間中に流路が閉塞したのではないかと考えられる。
:マトリゲル=1:1の割合で混ぜた細胞なしハイドロゲルを用いて4つの支持部材アレイを用いて上記と同様にゲル構造体を製作し、DMEM培地の中に入れ、1日間インキュベーターで培養した。垂直培養と平行培養で流路3にインクを流した結果が図10である。
コラーゲンゲル100%を用いた平行培養の結果を記す。この実験の目的はコラーゲンゲルのみを用いた場合には、平行培養でも筋組織の培養が可能であることを示すことにある。本実験では7日間培養後にアルギン酸ゲルを流路に流したときに、反対側から流路に残っていたと考えられる赤色の培養液が押し出されたことから、流路は開通したままであることがわかる。
灌流の有無で培養中の組織の自発的な収縮の程度が異なることを確認した。具体的には、培養36時間後に灌流ありの組織は最初に比べて39%幅が収縮した(図11)。また、灌流なしよりも灌流ありの方が収縮率は大きかった(図12)。以上より、収縮率が大きい灌流ありの方が灌流なしよりも細胞を活発に活動させることがわかる。
図13は36時間後の組織をアルギン酸ゲルに包埋した写真とメッシュアンカー11の部分を拡大した写真である。幅が39%収縮するほどテンションがかかっても筋組織がアンカリングされていることが示された。
筋組織の配向指標を確認するために、筋組織の周縁部を蛍光色素で染色して観察した。152時間灌流培養後において、筋組織の培地に触れている部分の蛍光染色画像を図14 (a))に示す。赤がファロイジンで染めたアクチンフィラメントであり、青がヘキストで染めた核である。一つの筋管の上に多くの核が乗っていることを確認でき、筋芽細胞が融合したことがわかる。また、アクチンフィラメントのみの画像からアクチンの方向分布を示した図が図14(b)である。0度にピークが立っていることが確認できるので、筋組織がO度の方向に配向していることがわかる。
36時間培養後の筋組織を切断し、live/deadアッセイをしたものを共焦点顕微鏡で観察した結果が図15である。切断した面は細胞が死ぬことが考えらえるため、34μm切断面から組織の内部を観察した。生細胞は196個、死細胞は725個であり、生存率は21%と低かった。細胞の生存率が低かった原因としては、組織の切断時に損傷したことが考えられる。組織の切断面より34μm内部の組織を観察しているが、切断する際に組織が引っ張られて細胞にダメージを与えている可能性が考えられる。
垂直培養によって支持部材8,9とアンカー11が機能していることを確認するために、培養後の細胞の様子をHE染色と蛍光免疫染色画像を用いて観察した。
(i) 7日間培養後の収縮率が大きい順にw/perfusion、w/o perfusion、w/o anchorとなった。
(ii) w/o perfusionでは筋組織が支持部材から脱落するものが存在した。
w/perfusionはw/o perfusionよりも灌流の効果で細胞が多く生きていたと考えられるので、収縮に関与する細胞の量もw/perfusionの方が多いと考えられる。したがって、w/ perfusionの方がw/o perfusionの方より収縮幅が大きくなったと考えられる。
培養後に収縮しても流路3が開通したままで、培養液が灌流されていたかをインクを流すことにより確認した。培養7日後に培養液を流していたチューブからインクを下から上に流した(図18)。また、図18の0秒の白い横線が組織内の支持部材の始まりである。白の実線がインクの位置を示し、矢印の長さはインクの流れた距離を表しており、横軸に時間を取ってプロットしたものを図19に示す。組織内に流路は4本あるが、重なって見えるので実際には2本のみ見えるはずである。そのうち1本のみしか見えないのは、流路が途中で潰れたのでインクが流れなかったと考えられる。また、時間に対して流れた距離は線形に増加すると考えられるが、実際にはそうはなっていなかった(図19)。これは図18の組織下部の穴によってインクが漏れ出ていたからであると考えられる。つまり流圧が孔のせいで弱まってしまったため上まで登り切らなかったと考えられる。
前述のものと異なるサンプルからクライオで製作した長辺の切片にも流路が確認された(図20)。2 x 2の流路が筋組織サンプルには存在するが、一つの面に存在するのは2つである。それぞれの流路の幅は193μmと137μmであった。幅が異なる原因は培養中に収縮の不均ーさによるものと考えられる。
流路に垂直な断面と平行に8μm厚の切片を製作し、HE染色を行った。ここで、核が中心部に存在していない原因について説明する。図21(a)がHE染色画像である。灌流が失敗していることがインク流し実験で確認できたサンプルであったため、中心部の核が存在しないことが確認できた。存在しないのは核が脱核して存在しなくなったのか、培養液を求めて周縁部に寄っていったのかのどちらかであると考えられる。特に図21(c)のように核が密集している周縁部は複数の核が一つの核とカウントされやすいので闘値の決定は慎重に行った。図21(d)のようになるように闘値を決め、図21(e)のようにカウントした。
灌流ありの筋組織サンプルと、灌流なしの筋組織サンプルについて、細胞濃度を比較した(図23)。図23(a)が灌流ありのサンプルであり、図23(b)が灌流なしのサンプルである。図23(a)では、孔が空いていることがわかる。両サンプルについて100μm×50μmの長方形の部分の細胞濃度を比較した(図23(c))。この結果、両サンプル共に組織のエッジから離れると細胞濃度は低下するが、灌流ありのサンプルでは、細胞濃度の減少が緩やかになることがわかった。これは灌流によって内部からも酸素や栄養素が供給されたことが要因であると考えられる。
灌流に成功したサンプルでは、流路の周りに核が密集していることがわかる(図24(a))。灌流なしのサンプル(図24(b))では、筋組織の外縁から遠ざかると細胞濃度は減少していく傾向にあるが、灌流ありのサンプルでは、流路に近づくと細胞濃度が上がっていくことがわかる(図24(c))。これは組織の周囲と同程度に豊富に酸素と栄養素を含んだ培養液が送液されたことによるものと考えられる。
振とうなしで8日間培養した組織のアクチンフィラメントの配向指標について検討した。図25の上段は組織の表面のアクチンフィラメントと核を染めたものであり、下段は組織の内部を同様に染めたものであり、上段と下段にそれぞれw/perfusionのサンプル、w/o perfusionのサンプル、w/o anchorのサンプルの結果を示す。図26は下段のアクチンフィラメントの配向指標を示したものである。アンカーあり灌流ありのサンプル(with perfusion)が、配向指標の高い筋組織になっていることが分かった。
2 培養空間
3 流路
4 第1コネクタ
5 第2コネクタ
6 培養液導入口
7 培養液排出口
8 第1支持部材
9 第2支持部材
10 流路形成部材
11 筋組織アンカー
12 ポンプ
13 骨格筋芽細胞
14 栄養分等
15 培養液
16 筋組織
17 基材
18 側壁
19 開口部(第1コネクタ及び/又は第2コネクタに形成されたもの)
20 封止材
Claims (8)
- 培養空間を有する培養槽、
前記培養空間内の互いに対向する位置に設けられた第1コネクタと第2コネクタ、
前記第1コネクタに設けられた培養液導入口、
前記第1コネクタに複数設けられ、かつ、前記培養液導入口から導入された培養液を吐出可能な第1支持部材、
前記第2コネクタに複数設けられ、かつ、培養液が流入可能な第2支持部材、
第1支持部材及び/又は第1コネクタに係合された第1筋組織アンカー、
第2支持部材及び/又は第2コネクタに係合された第2筋組織アンカーを備えた、三次元筋組織構築デバイス。 - 第1支持部材と第2支持部材に係合する培養液の流路形成部材をさらに備える、請求項1に記載の三次元筋組織構築デバイス。
- 前記培養液導入口へ培養液を供給するためのポンプをさらに備えた、請求項1又は2に記載の三次元筋組織構築デバイス。
- 請求項1~3のいずれかに記載の三次元筋組織構築デバイスにおいて、流路形成部材を第1支持部材と第2支持部材に挿通した状態で骨格筋芽細胞を含むハイドロゲルを第1コネクタと第2コネクタの間の培養空間に充填し、ハイドロゲルが固まった後に前記流路形成部材を脱着し、培養液を前記培養液導入口から第1支持部材を通って第2支持部材に供給し、骨格筋芽細胞を三次元培養する工程を含む、三次元筋組織の製造方法。
- 培養液を輸送可能な少なくとも1つの流路、
同一方向に配向した筋線維を備えた、三次元筋組織。 - 隣接する流路の間隔が500~1500μmである、請求項5に記載の三次元筋組織。
- 流路と筋線維の配向方向が略平行である、請求項5又は6に記載の三次元筋組織。
- 実質的にヘムを含まない、請求項5~7のいずれか1項に記載の三次元筋組織。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18/245,455 US20240026260A1 (en) | 2020-09-15 | 2021-09-02 | Device for forming three-dimensional muscle tissue and method of producing three-dimensional muscle tissue |
JP2022550456A JPWO2022059498A1 (ja) | 2020-09-15 | 2021-09-02 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2020154316 | 2020-09-15 | ||
JP2020-154316 | 2020-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022059498A1 true WO2022059498A1 (ja) | 2022-03-24 |
Family
ID=80776919
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2021/032244 WO2022059498A1 (ja) | 2020-09-15 | 2021-09-02 | 三次元筋組織構築デバイス及び三次元筋組織の製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240026260A1 (ja) |
JP (1) | JPWO2022059498A1 (ja) |
WO (1) | WO2022059498A1 (ja) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010539935A (ja) * | 2007-09-24 | 2010-12-24 | ノーティス,インク. | 灌流可能な微小血管システムを作製するための方法 |
JP2019122335A (ja) * | 2018-01-18 | 2019-07-25 | 国立大学法人 東京大学 | 人工三次元組織のバリア機能測定システム、人工三次元組織のバリア機能測定方法及び人工三次元組織を用いた薬剤評価方法 |
WO2020179257A1 (ja) * | 2019-03-04 | 2020-09-10 | 日清食品ホールディングス株式会社 | 三次元筋組織とその製造方法 |
-
2021
- 2021-09-02 US US18/245,455 patent/US20240026260A1/en active Pending
- 2021-09-02 WO PCT/JP2021/032244 patent/WO2022059498A1/ja active Application Filing
- 2021-09-02 JP JP2022550456A patent/JPWO2022059498A1/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010539935A (ja) * | 2007-09-24 | 2010-12-24 | ノーティス,インク. | 灌流可能な微小血管システムを作製するための方法 |
JP2019122335A (ja) * | 2018-01-18 | 2019-07-25 | 国立大学法人 東京大学 | 人工三次元組織のバリア機能測定システム、人工三次元組織のバリア機能測定方法及び人工三次元組織を用いた薬剤評価方法 |
WO2020179257A1 (ja) * | 2019-03-04 | 2020-09-10 | 日清食品ホールディングス株式会社 | 三次元筋組織とその製造方法 |
Non-Patent Citations (1)
Title |
---|
ISHII, Y. ET AL.: "FORMATION OF MICRO-SEE PERFUSABLE CHANNELS IN MM- THICK MUSCLE TISSUE", MEMS 2020, VANCOUVER, CANADA ., 18 January 2020 (2020-01-18), pages 456 - 458, XP033753102, DOI: 10.1109/MEMS46641.2020.9056142 * |
Also Published As
Publication number | Publication date |
---|---|
JPWO2022059498A1 (ja) | 2022-03-24 |
US20240026260A1 (en) | 2024-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102388127B (zh) | 肺的组织改造 | |
ES2685638T3 (es) | Carne comestible producida artificialmente | |
CN105311677B (zh) | 用于医疗移植物的细胞接种的方法、基底和系统 | |
JP7240028B2 (ja) | 細胞から組織を製造する装置および方法 | |
US20220169962A1 (en) | Three-dimensional muscle tissue and production method therefor | |
US20120183944A1 (en) | Decellularization and recellularization of organs and tissues | |
WO2022059498A1 (ja) | 三次元筋組織構築デバイス及び三次元筋組織の製造方法 | |
WO2024024929A1 (ja) | 三次元筋組織の製造方法 | |
JP2004505746A (ja) | 血管化組織移植片 | |
CN115551995A (zh) | 通过生物打印制造的肌肉组织 | |
US10632229B2 (en) | Tissue engineering | |
CN105309346A (zh) | 一种用组织工程支架珠核培育珍珠的方法 | |
WO2023152489A1 (en) | Bioreactor | |
WO2023147288A1 (en) | Methods for cell culturing | |
WO2023152493A1 (en) | Substrate assembly, cell culture method, bioreactor and cultured meat product | |
WO2022162662A1 (en) | 3d-printable protein-enriched scaffolds | |
KR20210043885A (ko) | 인공 식도 지지체 및 이의 제조 방법 | |
Rinaldi | Optimization of Silk Scaffold for Cardiac Tissue Engineering |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21869185 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022550456 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18245455 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21869185 Country of ref document: EP Kind code of ref document: A1 |